These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. A new approach to initial antiretroviral therapy: protease-sparing combination regimens. Hanna L BETA; 1998 Oct; ():9-13. PubMed ID: 11365999 [TBL] [Abstract][Full Text] [Related]
6. What's new and what's next. Fakuda D Posit Dir News; 1998 Jan; 10(1):25-9. PubMed ID: 11365053 [TBL] [Abstract][Full Text] [Related]
7. Fifth Conference on Retroviruses & Opportunistic Infections. Interview by Ron Baker. Follansbee S; Deeks S; Bartnoff H Newsline People AIDS Coalit N Y; 1998 Mar; ():7-14. PubMed ID: 11367453 [TBL] [Abstract][Full Text] [Related]
8. The latest antiviral news. Vazquez E Posit Aware; 1999; 10(2):44. PubMed ID: 11366851 [TBL] [Abstract][Full Text] [Related]
9. New study shows efavirenz effective with d4T and 3TC. AIDS Alert; 1999 May; 14(5):60. PubMed ID: 11366404 [TBL] [Abstract][Full Text] [Related]
10. Antiretroviral update from the Interscience Conference on Antimicrobial Agents and Chemotherapy. Newsline People AIDS Coalit N Y; 1998 Dec; ():16-8. PubMed ID: 11367083 [TBL] [Abstract][Full Text] [Related]
11. Protease inhibitor failure trial: combination 1592, 141W94, and efavirenz. AIDS Treat News; 1997 Dec; (No 284):4. PubMed ID: 11364914 [TBL] [Abstract][Full Text] [Related]
12. A new HAART on the horizon says the proof is in the potency. AIDS Alert; 1999 Apr; 14(4):37-9. PubMed ID: 11366218 [TBL] [Abstract][Full Text] [Related]
13. New drugs in development. Proj Inf Perspect; 1998 Sep; (25):8. PubMed ID: 11365851 [TBL] [Abstract][Full Text] [Related]
14. Four new antiretroviral medications will soon offer more options to HIV patients. Murphy MJ Fac Notes (New Orleans La); 1998; 10(4):1-3. PubMed ID: 11365545 [TBL] [Abstract][Full Text] [Related]
15. Novel approaches for the treatment of HIV. Arroyo HT Newsline People AIDS Coalit N Y; 1998 Mar; ():16-7. PubMed ID: 11367450 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of abacavir plus efavirenz as a salvage regimen in HIV-infected individuals after 48 weeks. Wasmuth JC; Herhaus C; Römer K; Salzberger B; Kaiser R; Schliefer K; Voigt E; Rockstroh JK AIDS; 2002 May; 16(7):1077-8. PubMed ID: 11953478 [No Abstract] [Full Text] [Related]
17. Switch to efavirenz in a protease inhibitor-containing regimen. Knechten H; Stürner KH; Höhn C; Braun P HIV Clin Trials; 2001; 2(3):200-4. PubMed ID: 11590528 [TBL] [Abstract][Full Text] [Related]
18. Anti-HIV therapy trials: new studies and follow-up of existing trials. Bartnof HS BETA; 1999; 12(4):58-60. PubMed ID: 11367257 [TBL] [Abstract][Full Text] [Related]